A study featuring a new colonoscope that allows doctors to see more of the colon shows promise that could revolutionize colorectal cancer screening.
Researchers compared both the adenoma miss rate using the new colonoscope with the miss rate of a traditional colonoscope. The miss rate for the new colonoscope was only 7.6 percent as compared to 41.7 percent for the traditional colonoscope, in this study.
"It's always our goal to minimize miss rates in colonoscopy. These results show us a way to achieve that and improve the efficacy of colorectal cancer screening and surveillance colonoscopy," said Professor Ian M. Gralnek of the Bruce and Ruth Rappaport Faculty of Medicine, Technion-Israel Institute of Technology and senior physician at the department of gastroenterology, Rambam Health Care Campus and Elisha Hospital in Haifa, Israel.
Developed by EndoChoice, the Full Spectrum Endoscopy (FUSE) colonoscope maintains the identical technical features of the standard colonoscope, but allows the endoscopist to view 330 degrees, compared to the 170 degree viewing angle of the traditional colonoscope.
The study randomly assigned 197 patients for tandem colonoscopies using either the standard or the FUSE colonoscope first. In addition to a significantly lower adenoma miss rate, results showed a significantly higher adenoma detection rate favoring FUSE.
Professor Gralnek credits FUSE's improved imaging technology with these findings as adenomas can be difficult to detect with only forward-viewing capabilities.
The additional information FUSE provides to doctors may allow them to adjust patients' surveillance intervals according to risk level, ultimately helping to prevent incremental colorectal cancers. The FUSE scope could be available as early as this summer.
The research was presented at Digestive Disease Week (DDW). (ANI)